European Medicines Agency approves first-line cabozantinib for advanced kidney cancer
Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal [...]
Ipilimumab-nivolumab combination improves overall survival in metastatic kidney cancer
Overall survival data for the ipilimumab-nivolumab combination versus sunitinib from [...]
EAU guidelines for the treatment of first-line metastatic kidney cancer to be updated
Further to the results from recent studies, particularly CheckMate-214, the [...]
Adjuvant sunitinib declined by European Medicines Agency committee
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
Tyrosine kinase inhibitors for kidney cancer: Past, present and future
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
The future of immuno-oncology in kidney cancer
In his keynote lecture at the American Society for Clinical [...]
Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer
The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]
Sequencing of treatments for advanced kidney cancer remains uncertain
There are now a number of licensed drug options available [...]
Adjuvant therapy for renal cell carcinoma
The following article is a good review of the data [...]
